Fibroblast growth factor signalling in multiple sclerosis: Inhibition of myelination and induction of pro-inflammatory environment by FGF9

Brain

Volumn 138, Issue 7, 2015, Pages 1875-1893

  Lindner, Maren ^a   Thümmler, Katja ^a   Arthur, Ariel ^a   Brunner, Sarah ^b   Elliott, Christina ^a   McElroy, Daniel ^a   Mohan, Hema ^c   Williams, Anna ^d   Edgar, Julia M ^a   Schuh, Cornelia ^e   Stadelmann, Christine ^f   Barnett, Susan C ^a   Lassmann, Hans ^e   Mücklisch, Steve ^g   Mudaliar, Manikhandan ^h   Schaeren Wiemers, Nicole ^b   Meinl, Edgar ^c   Linington, Christopher ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

^g CHEMNITZ UNIVERSITY OF TECHNOLOGY   (Germany)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

chemokines; FGF; inflammation; multiple sclerosis (MS); remyelination

Indexed keywords

ENZYME; FIBROBLAST GROWTH FACTOR 9; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 3; PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; FGF9 PROTEIN, HUMAN; FGF9 PROTEIN, MOUSE; FGF9 PROTEIN, RAT;

ADULT; AGED; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CELL INTERACTION; CELL LINEAGE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATION; DISEASE ASSOCIATION; EMBRYO; EXTRACELLULAR MATRIX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INFLAMMATION; MACROPHAGE; MALE; MICROGLIA; MIDDLE AGED; MULTIPLE SCLEROSIS; MYELIN SHEATH; MYELINATION; NERVE FIBER; NEUROPATHOLOGY; NONHUMAN; OLIGODENDROGLIA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; REMYELINIZATION; SIGNAL TRANSDUCTION; TISSUE INJURY; VERY ELDERLY; ANIMAL; CELL CULTURE; DEMYELINATING DISEASE; DNA MICROARRAY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; METABOLISM; MOUSE; ORGAN CULTURE TECHNIQUE; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ASTROCYTES; CELLS, CULTURED; DEMYELINATING DISEASES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 9; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INFLAMMATION; MALE; MICE; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; MULTIPLE SCLEROSIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGAN CULTURE TECHNIQUES; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

EID: 84936806384     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv102     Document Type: Article

References (84)

1. Azim K, Raineteau O, Butt AM. Intraventricular injection of FGF-2 promotes generation of oligodendrocyte-lineage cells in the postnatal and adult forebrain. Glia 2012; 60: 1977-90.
2. Back SA, Tuohy TM, Chen H, Wallingford N, Craig A, Struve J, et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med 2005; 11: 966-72.
3. Bansal R. Fibroblast growth factors and their receptors in oligodendrocyte development: implications for demyelination and remyelination. Dev Neurosci 2002; 24: 35-46.
4. Bansal R, Pfeiffer SE. Inhibition of protein and lipid sulfation in oligodendrocytes blocks biological responses to FGF-2 and retards cytoarchitectural maturation, but not developmental lineage progression. Dev Biol 1994; 162: 511-24.
5. Bottenstein JE, Sato GH. Growth of rat neuroblastoma cell line in serum-free supplemented medium. Proc Natl Acad Sci USA 1979; 76: 514-17.
6. Bugiani M, Postma N, Polder E, Dieleman N, Scheffer PG, Sim FJ, et al. Hyaluronan accumulation and arrested oligodendrocyte progenitor maturation in vanishing white matter disease. Brain 2013; 136: 209-22.
7. Butt AM, Dinsdale J. Fibroblast growth factor 2 induces loss of adult oligodendrocytes and myelin in vivo. Exp Neurol 2005; 192: 125-33.
8. Carpenter AE, Jones TR, Lamprecht MR, Clarke C, Kang IH, Friman O, et al. CellProfiler: image analysis software for identifying and quantifying cell phenotypes. Genome Biol 2006; 7: R100.
9. Chang A, Staugaitis SM, Dutta R, Batt CE, Easley KE, Chomyk AM, et al. Cortical remyelination: a new target for repair therapies in multiple sclerosis. Ann Neurol 2012; 72: 918-26.
10. Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med 2002; 346: 165-73.
11. Clemente D, Ortega MC, Arenzana FJ, de Castro F. FGF-2 and Anosmin-1 are selectively expressed in different types of multiple sclerosis lesions. Neurosci 2011; 31: 14899-909.
12. Cohen R, Chandross K. Fibroblast growth factor-9 modulates the expression of myelin related proteins and multiple fibroblast growth factor receptors in developing oligodendrocytes. J Neurosci Res 2000; 61: 273-87.
13. Deshmukh VA, Tardif V, Lyssiotis CA, Green CC, Kerman B, Kim HJ, et al. A regenerative approach to the treatment of multiple sclerosis. Nature 2013; 502: 327-32.
14. Duncan ID, Brower A, Kondo Y, Curlee JF, Schultz RD. Extensive remyelination of the CNS leads to functional recovery. Proc Natl Acad Sci USA 2009; 106: 6832-6.
15. Elliott C, Lindner M, Arthur A, Brennan K, Jarius S, Hussey J, et al. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain 2012; 135: 1819-33.
16. Fortin D, Rom E, Sun H, Yayon A, Bansal R. Distinct fibroblast growth factor (FGF)/FGF receptor signaling pairs initiate diverse cellular responses in the oligodendrocyte lineage. J Neurosci 2005; 25: 7470-9.
17. Franklin RJ, Ffrench-Constant C. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci 2008; 9: 839-55.
18. Franklin RJ, Ffrench-Constant C, Edgar JM, Smith KJ. Neuroprotection and repair in multiple sclerosis. Nat Rev Neurol 2012; 8: 624-34.
19. Fuentes ME, Durham SK, Swerdel MR, Lewin AC, Barton DS, Megill JR, et al. Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J Immunol 1995; 155: 5769-76.
20. Fünfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature 2012; 485: 517-21.
21. Furusho M, Dupree JL, Nave KA, Bansal R. Fibroblast growth factor receptor signaling in oligodendrocytes regulates myelin sheath thickness. J Neurosci 2012; 32: 6631-41.
22. Furusho M, Kaga Y, Ishii A, Hébert JM, Bansal R. Fibroblast growth factor signaling is required for the generation of oligodendrocyte progenitors from the embryonic forebrain. J Neurosci 2011; 31: 5055-66.
23. Goddard DR, Berry M, Kirvell SL, Butt AM. Fibroblast growth factor-2 inhibits myelin production by oligodendrocytes in vivo. Mol Cell Neurosci 2001; 18: 557-69.
24. Goetz R, Mohammadi M. Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol 2013; 14: 166-80.
25. Goldschmidt T, Antel J, König FB, Brück W, Kuhlmann T. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology 2009; 72: 1914-21.
26. Graumann U, Reynolds R, Steck AJ, Schaeren-Wiemers N. Molecular changes in normal appearing white matter in multiple sclerosis are characteristic of neuroprotective mechanisms against hypoxic insult. Brain Pathol 2003; 13: 554-73.
27. Guillemot F, Zimmer C. From cradle to grave: the multiple roles of fibroblast growth factors in neural development. Neuron 2011; 71: 574-88.
28. Harada M, Murakami H, Okawa A, Okimoto N, Hiraoka S, Nakahara T, et al. FGF9 monomer-dimer equilibrium regulates extracellular matrix affinity and tissue diffusion. Nat Genet 2009; 41: 289-98.
29. Hecht D, Zimmerman N, Bedford M, Avivi A, Yayon A. Identification of fibroblast growth factor 9 (FGF9) as a high affinity, heparin dependent ligand for FGF receptors 3 and 2 but not for FGF receptors 1 and 4. Growth Factors 1995; 12: 223-33.
30. Howell MD, Gottschall PE. Lectican proteoglycans, their cleaving metalloproteinases, and plasticity in the central nervous system extracellular microenvironment. Neuroscience 2012; 217: 6-18.
31. Irvine KA, Blakemore WF. Remyelination protects axons from demyelination-associated axon degeneration. Brain 2008; 131: 1464-77.
32. Ishibashi T, Dakin KA, Stevens B, Lee PR, Kozlov SV, Stewart CL, et al. Astrocytes promote myelination in response to electrical impulses. Neuron 2006; 49: 823-32.
33. Kotter MR, Stadelmann C, Hartung HP. Enhancing remyelination in disease-can we wrap it up? Brain 2011; 134: 1882-900.
34. Kuhlmann T, Miron V, Cui Q, Wegner C, Antel J, Bruck W. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 2008; 131: 1749-58.
35. Lassmann H, van Horssen J, Mahad D. Progressive multiple sclerosis: pathology and pathogenesis. Nature Rev Neurol 2012; 8: 647-56.
36. Lau LW, Cua R, Keough MB, Haylock-Jacobs S, Yong VW. Pathophysiology of the brain extracellular matrix: a new target for remyelination. Nat Rev Neurosci 2013; 14: 722-9.
37. Linington C, Engelhardt B, Kapocs G, Lassman H. Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody. J Neuroimmunol 1992; 40: 219-24.
38. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
39. McKinnon RD, Matsui T, Dubois-Dalcq M, Aaronson SA. FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 1990; 5: 603-14.
40. McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J Neuroimmunol 1998; 86: 20-9.
41. Mahad DJ, Ransohoff RM. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). Semin Immunol 2003; 15: 23-32.
42. Maier O, van der Heide T, van Dam AM, Baron W, de Vries H, Hoekstra D. Alteration of the extracellular matrix interferes with raft association of neurofascin in oligodendrocytes. Potential significance for multiple sclerosis? Mol Cell Neurosci 2005; 28: 390-401.
43. Mierzwa AJ, Zhou YX, Hibbits N, Vana AC, Armstrong RC. FGF2 and FGFR1 signaling regulate functional recovery following cuprizone demyelination. Neurosci Lett 2013; 548: 280-5.
44. Mohan H, Friese A, Albrecht S, Krumbholz M, Elliott CL, Arthur A, et al. Transcript profiling of different types of multiple sclerosis lesions yields FGF1 as a promoter of remyelination. Acta Neuropathol Commun 2014; 2: 178.
45. Nave KA. Myelination and support of axonal integrity by glia. Nature 2010; 468: 244-52.
46. Oh LY, Denninger A, Colvin JS, Vyas A, Tole S, Ornitz DM, et al. Fibroblast growth factor receptor 3 signaling regulates the onset of oligodendrocyte terminal differentiation. J Neurosci 2003; 23: 883-94.
47. Patani R, Balaratnam M, Vora A, Reynolds R. Remyelination can be extensive in multiple sclerosis despite a long disease course. Neuropathol Appl Neurobiol 2007; 33: 277-87.
48. Patel JR, McCandless EE, Dorsey D, Klein RS. CXCR4 promotes differentiation of oligodendrocyte progenitors and remyelination. Proc Natl Acad Sci USA 2010; 107: 11062-7.
49. Patrikios P, Stadelmann C, Kutzelnigg A, Rauschka H, Schmidbauer M, Laursen H, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006; 129: 3165-72.
50. Piaton G, Williams A, Seilhean D, Lubetzki C. Remyelination in multiple sclerosis. Prog Brain Res 2009; 175: 453-64.
51. Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol 1993; 33: 137-51.
52. Prineas JW, Connell F. Remyelination in multiple sclerosis. Ann Neurol 1979; 5: 22-31.
53. Raine CS, Wu E. Multiple sclerosis: remyelination in acute lesions. J Neuropathol Exp Neurol 1993; 52: 199-204.
54. Redford EJ, Kapoor R, Smith KJ. Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 1997; 120: 2149-57.
55. Renner NA, Ivey NS, Redmann RK, Lackner AA, MacLean AG. MCP-3/CCL7 production by astrocytes: implications for SIV neuroinvasion and AIDS encephalitis. J Neurovirol 2011; 17: 146-52.
56. Reuss B, Hertel M, Werner S, Unsicker K. Fibroblast growth factors-5 and-9 distinctly regulate expression and function of the gap junction protein connexin43 in cultured astroglial cells from different brain regions. Glia 2000; 30: 231-41.
57. Rottlaender A, Villwock H, Addicks K, Kuerten S. Neuroprotective role of fibroblast growth factor-2 in experimental autoimmune encephalomyelitis. Immunology 2011; 133: 370-378.
58. Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 2000; 132: 365-86.
59. Ruffini F, Furlan R, Poliani PL, Brambilla E, Marconi PC, Bergami A, et al. Fibroblast growth factor-II gene therapy reverts the clinical course and the pathological signs of chronic experimental autoimmune encephalomyelitis in C57BL/6 mice. Gene Ther 2001; 8: 1207-13.
60. Sarchielli P, Di Filippo M, Ercolani MV, Chiasserini D, Mattioni A, Bonucci M, et al. Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. Neurosci Lett 2008; 435: 223-8.
61. Schaeren-Wiemers N, Gerfin-Moser A. A single protocol to detect transcripts of various types and expression levels in neural tissue and cultured cells: in situ hybridization using digoxigenin-labelled cRNA probes. Histochemistry 1993; 100: 431-40.
62. Scolding NJ, Rayner PJ, Compston DA. Identification of A2B5-positive putative oligodendrocyte progenitor cells and A2B5-positive astrocytes in adult human white matter. Neuroscience 1999; 89: 1-4.
63. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-8.
64. Seuntjens E, Nityanandam A, Miquelajauregui A, Debruyn J, Stryjewska A, Goebbels S, et al. Sip1 regulates sequential fate decisions by feedback signaling from postmitotic neurons to progenitors. Nat Neurosci 2009; 12: 1373-80.
65. Shen S, Sandoval J, Swiss VA, Li J, Dupree J, Franklin RJ, et al. Agedependent epigenetic control of differentiation inhibitors is critical for remyelination efficiency. Nat Neurosci 2008; 11: 1024-34.
66. Siebert JR, Osterhout DJ. The inhibitory effects of chondroitin sulfate proteoglycans on oligodendrocytes. J Neurochem 2011; 119: 176-88.
67. Sisková Z, Baron W, de Vries H, Hoekstra D. Fibronectin impedes "myelin" sheet-directed flow in oligodendrocytes: a role for a beta 1 integrin-mediated PKC signaling pathway in vesicular trafficking. Mol Cell Neurosci 2006; 33: 150-9.
68. Sisková Z, Yong VW, Nomden A, van Strien M, Hoekstra D, Baron W. Fibronectin attenuates process outgrowth in oligodendrocytes by mislocalizing MMP-9 activity. Mol Cell Neurosci 2009; 42: 234-42.
69. Stark JL, Cross AH. Differential expression of suppressors of cytokine signaling-1 and-3 and related cytokines in central nervous system during remitting versus non-remitting forms of experimental autoimmune encephalomyelitis. Int Immunol 2006; 18: 347-53.
70. Sloane JA, Batt C, Ma Y, Harris ZM, Trapp B, Vartanian T. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc Natl Acad Sci USA 2010; 107: 11555-60.
71. Stoffels JM, de Jonge JC, Stancic M, Nomden A, van Strien ME, Ma D, et al. Fibronectin aggregation in multiple sclerosis lesions impairs remyelination. Brain 2013; 136: 116-31.
72. Stankoff B, Aigrot MS, Noël F, Wattilliaux A, Zalc B, Lubetzki C. Ciliary neurotrophic factor (CNTF) enhances myelin formation: a novel role for CNTF and CNTF-related molecules. J Neurosci 2002; 22: 9221-7.
73. Tacer KF, Bookout AL, Ding X, Kurosu H, John GB, Wang L, et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol 2010; 24: 2050-64.
74. Thompson WL, Van Eldik LJ. Inflammatory cytokines stimulate the chemokines CCL2/MCP-1 and CCL7/MCP-3 through NFkB and MAPK dependent pathways in rat astrocytes. Brain Res 2009; 1287: 47-57.
75. Tobin JE, Xie M, Le TQ, Song SK, Armstrong RC. Reduced axonopathy and enhanced remyelination after chronic demyelination in fibroblast growth factor 2 (Fgf2)-null mice: differential detection with diffusion tensor imaging. J Neuropathol Exp Neurol 2011; 70: 157-65.
76. Todo T, Kondo T, Nakamura S, Kirino T, Kurokawa T, Ikeda K. Neuronal localization of fibroblast growth factor-9 immunoreactivity in human and rat brain. Brain Res 1998; 783: 179-87.
77. Tripathi RB, Rivers LE, Young KM, Jamen F, Richardson WD. NG2 glia generate new oligodendrocytes but few astrocytes in a murine experimental autoimmune encephalomyelitis model of demyelinating disease. J Neurosci 2010; 30: 16383-90.
78. Trujillo JA, Fleming EL, Perlman S. Transgenic CCL2 expression in the central nervous system results in a dysregulated immune response and enhanced lethality after coronavirus infection. J Virol 2013; 87: 2376-89.
79. Tuohy TM, Wallingford N, Liu Y, Chan FH, Rizvi T, Xing R, et al. CD44 overexpression by oligodendrocytes: a novel mouse model of inflammation-independent demyelination and dysmyelination. Glia 2004; 47: 335-45.
80. Weng Q, Chen Y, Wang H, Xu X, Yang B, He Q, et al. Dual-mode modulation of Smad signaling by Smad-interacting protein Sip1 is required for myelination in the central nervous system. Neuron 2012; 73: 713-28.
81. Wolswijk G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain 2002; 125: 338-49.
82. Young KM, Mitsumori T, Pringle N, Grist M, Kessaris N, Richardson WD. An Fgfr3-iCreER(T2) transgenic mouse line for studies of neural stem cells and astrocytes. Glia 2010; 58: 943-53.
83. Zhang H, Jarjour AA, Boyd A, Williams A. Central nervous system remyelination in culture-a tool for multiple sclerosis research. Exp Neurol 2011; 230: 138-48.
84. Zhang Y, Taveggia C, Melendez-Vasquez C, Einheber S, Raine CS, Salzer JL, et al. Interleukin-11 potentiates oligodendrocyte survival and maturation, and myelin formation. J Neurosci 2006; 26: 12174-85.